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ABSTRACT Multiple forms of proteasomes regulate cellular processes by destroying proteins or forming the peptides 
involved in those processes. Various pathologies, including carcinogenesis, are related to changes in the functioning of 
the proteasome forms. In this study, we looked at the changes in the pool of liver proteasomes during nodular regen-
erative hyperplasia and formation of adenoma and hepatocellular carcinoma in mice treated with Dipin, followed by 
partial liver resection. The relative content of various proteasome forms was determined using Western blot analysis. 
The chymotrypsin-like activity of proteasomes was assessed from the hydrolysis of the commercial Suc-LLVY-AMC 
substrate. It was found that changes in the proteasome pool appeared already during the formation of diffuse nodules, 
the changes being the increased expression of the X(β5) constitutive subunit and the LMP7(β5i) and LMP2(β1i) immune 
subunits, accompanied by the increase of the total proteasome pool and the decrease in the chymotrypsin-like activity. 
These changes were more pronounced in hepatocellular carcinoma. The content of the total proteasome pool and the 
LMP2(β1i) immune subunit and the chymotrypsin-like activity in adenoma were intermediate compared to those in the 
samples of liver with diffuse nodules and carcinoma. In addition, the level of the Rpt6 subunit present in the 19S protea-
some activator was increased in carcinoma. Our results indicate that nodular regenerative hyperplasia and adenomatosis 
may be stages preceding carcinogenesis. We also conclude that there is a need to find signalling pathways that change the 
expression of various proteasome subunits during carcinogenesis. The 19S proteasome activator, which is overexpressed 
in malignant tumours, can be a promising target for the development of new anticancer drugs.
KEYWORDS immunoproteasomes, 19S proteasome activator, chymotrypsin-like activity of proteasomes, Western blot 
analysis, nodular regenerative hyperplasia of the liver, adenoma, hepatocellular carcinoma, mouse liver.
ABBREVIATIONS nNOS - neuronal nitric oxide synthase, dipin - 1,4-Bis-[N,N’-di(Ethylene)-phosphamide]piperazine, 
Suc-LLVY-AMC - N-succinyl-leu-leu-val-tyr7-amido-4-methyl coumarin, MG132 - Z-leucyl-leucyl-leucinal, mAb - 
monoclonal antibody, pAb - polyclonal antibody
INTRODUCTION
Understanding the molecular mechanisms underlying the 
malignant transformation of cells is of ever vital importance. 
The new protein hydrolysis system discovered in the 1980s 
involving proteasomes and affecting all cellular processes 
provided a new impulse to the studies of the mechanisms 
of mammalian cell malignant transformation. Proteasomes, 
multisubunit multiproteinase protein complexes, are present 
in mammalian organs and tissues in a multitude of forms of 
different structures and physiological functions [1–4]. Protea-
somes can be divided into two groups—constitutive proteas-
omes and immunoproteasomes—depending on the nature of 
their active protease subunits. The constitutive proteasomes 
contain two of each of the X(β5), Y(β1) and Z(β2) subunits, 
possessing chymotrypsin-like, caspase-like, and trypsin-like 
activity, respectively. The immunoproteasomes contain the 
LMP7(β5i), LMP2(β1i), and LMP10(β2i) immune subunits in-
stead of the above-mentioned protease active subunits of the 
constitutive proteasomes. When foreign proteins are hydro-
lysed by immunoproteasomes, the amount of antigen epitopes 
formed is several times higher. The antigen epitopes are ca-
pable of incorporating into the Bjorkman gap of the major 
histocompatibility complex class I molecules for further pre-
sentation to T lymphocytes. In addition, immunoproteasomes 
participate in the regulation of the differentiation and prolif-
eration of some cell populations, perhaps, by producing bio-
logically active peptides [5, 6]. They are also an essential part 
of the signalling pathway responsible for the quenching of 
oxidative stress [7].
Both constitutive proteasomes and immunoproteasomes 
form 26S and 20S proteasome pools [3]. The 26S proteasomes 
consist of the 20S proteolytic core particle and one or two of 
the 19S regulatory particles responsible for binding to ubiq-
uitinated target proteins, the unfolding of those proteins, and 
directing them into the proteolytic chamber. Thus, the 26S 
proteasomes regulate cellular processes by degrading pro-
teins or forming the peptides involved in those processes.They 
also trigger the reactions associated with the T-cell immune RESEARCH ARTICLES
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response. The 26S proteasomes are usually dependent on ATP 
and ubiquitin. The 20S proteasomes, on the contrary, degrade 
proteins and short peptides independently of ATP and ubiq-
uitin. The number of proteins identified as substrates of 20S 
proteasomes increases every year; these include, for example, 
proteins with a damaged tertiary structure [8] and some virus 
proteins [9, 10].
The functions of proteasomes are very diverse, and de-
termining the changes occurring in the proteasome pool 
during malignant cell transformation is important for un-
derstanding the transformation mechanism, as well as for 
finding new targets for anticancer therapy among the mul-
tiple forms of proteasomes. The scarce published data on 
this matter concern the comparison of separate proteasome 
form contents in malignant and control cells [11–16]. Infor-
mation on how the proteasome pool functions during the 
growth of nonmalignant and malignant tumours could shed 
light on some of the mechanisms of cell transformation into 
the malignant state. The aim of this study was to determine 
the changes in the proteasome pool during the growth of 
nonmalignant and malignant tumours using the same model 
animals. We used a previously developed model to induce 
malignant transformation of liver cells in mice CBA/Lac 
x BL/6 F1 by alkylating drug, Dipin, followed by partial 
liver resection [17, 18]. Dipin causes irreparable damage of 
the genetic material in hepatocytes leading, after mitoses 
stimulated by partial liver resection, to chromosome break-
age and rearrangement. The cells damaged in such a way 
are not viable, and they eventually die. The parenchyma is 
regenerated by means of activation of stem cells and clo-
nogenic growth of neoplastic hepatic nodules, which coa-
lesce and displace the original degenerating hepatocytes and 
form new tissue. This nodular regenerative hyperplasia is 
diffuse in nature, but, eventually, the separate nodules can 
progress and give rise to large adenomas and hepatocarci-
nomes. In this paper, we report on the comparative study 
of the chymotrypsin-like activity and total proteasome pool 
content, as well as the 26S proteasome and immunoprotea-
some contents, in the intact liver and induced nonmalignant 
and malignant liver tumours.
EXPERIMENTAL
Reagents. The following reagents were used: Suc-LLVY-
AMC and MG132 (Sigma, USA), anti-β-actin mouse mAb 
(Santa Cruz, Germany), anti-Rpt6 and anti-α1,2,3,5,6,7 mouse 
mAb, anti-X(β5), anti-LMP7(β5i) and anti-LMP2(β1i) rabbit 
pAb (Biomol, UK), anti-nNOS rabbit pAb (Abcam, UK), and 
ECL kit, Hybond-ECL nitrocellulose membranes and peroxi-
dase conjugated antibodies to mouse and rabbit IgG (Amer-
sham Biosciences, UK).
Animals. Male mice CBA/Lac x BL/6 F1, three months 
old, 20–22 g weight, were used in the study. Dipin at 60 mi-
crogram per 1 g of weight was injected to a group of male 
mice. A standard partial liver resection operation (up to 70 %) 
was performed according to a previously developed proce-
dure [17]. Mice with intact liver and mice subjected to partial 
liver resection were used as controls. After 12 months, the 
livers of the control and test animals were studied.
Histological study of the liver. The fragments of the liver 
and large tumour nodules were fixed in 10% formalin. The 
fixed material was processed following the standard proce-
dure: 5-micron-thick sections were prepared after paraffin 
embedding. After removing the paraffin, the specimens were 
H&E stained, embedded in balsam, and analysed with Olym-
pus AHBT3 optical microscope.
Preparation of clarified homogenates of liver and tumour 
fragments. All procedures were performed at 0–4 °С. Liver 
and tumour fragments were washed with a standard sodium 
phosphate buffer, dried, weighed, and homogenised (glass-
glass, homogeniser Braun Melsungen, Germany) in a buffer 
containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM 
EDTA, 1 mM dithiothreitol, 10% glycerine, 5 mM MgCl2, 1 
mM ATP, 10 mM Na2S2O5, leupeptin (0.5 μg/ml), pepstatin 
(1 μg/ml) and aprotinin (1 μg/ml) at 1 : 3 ratio. The homoge-
nates were centrifuged at 10,000 g for 30 min. The superna-
tants (clarified homogenates) were used in the studies. The 
protein concentration in the clarified homogenates was de-
termined by the Lowry method [19].
Determination of proteasome activity. The proteasome 
activity was determined by measuring the hydrolysis of the 
Suc-LLVY-AMC fluorogenic oligopeptide, which is a sub-
strate for proteasome chymotrypsin-like sites [20]. The reac-
tion mixture contained 20 mM Tris-HCl (pH 7.5), 1 mM dithi-
othreitol, 30 μM Suc-LLVY-AMC, 5 mM MgCl2, and 1 mM 
ATP. In order to eliminate the contribution of the proteolytic 
activity of impurities, 10 μM MG132 (inhibitor of the protea-
some chymotrypsin-like sites) was added to some samples. 
The reaction was carried out at 37 °С for 20 min after adding 
0.5–2 μl of clarified homogenate (to a total volume of 100 μl), 
and the reaction was stopped with 1% SDS. The product mix-
ture was measured in a fluorimeter with excitation and emis-
sion at 380 and 440 nm, respectively. The difference between 
the total and residual activity in the presence of MG132 was 
calculated. The activity was expressed as nanomol of Suc-
LLVY-AMC hydrolysed in 20 min by proteasomes contained 
in 100 μl of clarified homogenates.
Western blot analysis. Western blot analysis was used to 
determine the relative content of proteasome subunits, nNOS, 
and β-actin in the clarified homogenates. Gel electrophoresis 
of the proteins from clarified homogenates was performed 
in 10–13% PAA gel in the presence of SDS (5 μl per lane, 
120–148 μg of protein). The polypeptides were transferred 
from the gel to a nitrocellulose membrane using the semi-dry 
method. The membrane was incubated for 2 hours at 20 °С 
in TNT buffer (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% 
Tween-20), and then for 1 hour in TNT buffer containing 
2–5% of non-fat milk and mouse mAb to β-actin (1 : 200) or 
to Rpt6 (1 : 2500), or to α1,2,3,5,6,7 (1 : 2500) (or rabbit pAb to 
nNOS (1 : 500) or to X(β5), or to LMP7(β5i), or to LMP2(β1i) (1 
: 1250)). The membrane was washed several times with TNT 
buffer and incubated for 1 hour in TNT buffer containing 
2–5% of nonfat milk and peroxidase conjugated antibodies 
to mouse (or rabbit) IgG (1 : 2500). Then, the membrane was 
washed with TNT buffer and analysed using the ECL kit fol-
lowing the standard procedure.
ImageJ software was used for image processing. The rela-
tive content of proteins in the clarified homogenates was de-
termined by measuring the density of corresponding bands 
on the X-ray film, using previously prepared calibration plots 
of density vs. analysed protein content. Further experiments 104 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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were carried out within the range of protein concentrations 
for which the calibration plot showed linear behaviour.
Statistical analysis. The data are presented as average ± 
confidence interval (δ):
δ = ± tσ n–0.5,
where t is the Student’s criterion value at significance level p 
< 0.05, σ is the standard error, and n is the number of experi-
ments.
RESULTS AND DISCUSSION
Histological study of mouse liver. The results of mouse liver 
histological study performed 12 months after Dipin injection 
and partial liver resection are presented in Fig. 1. Multiple 
nodules (benign tumours, microadenomas) were revealed in 
the liver tissue (Fig. 1 a); they formed during the diffuse nod-
ular regenerative hyperplasia of hepatocytes. In addition, we 
detected large benign tumours, adenomas, (Fig. 1 b) and ma-
lignant tumours whose biological properties corresponded to 
hepatocellular carcinoma of the trabecular type (Fig. 1 c) [21]. 
We performed a comparative study of the chymotrypsin-like 
activity of the total proteasome pool and the content of vari-
ous proteasome subunits in the tumour samples and liver 
fragments with diffuse nodular hyperplasia versus liver sam-
ples of the control animals.
Technical notes on the study of changes in the proteasome 
pool during tumourogenesis. The relative content of the total 
proteasome pool in the samples was studied by Western blot 
analysis using antibodies to α1,2,3,5,6,7 subunits present in all 
proteasome forms. In a similar way, we determined the rela-
tive content of the 26S proteasomes using antibodies to the 
Rpt6 subunit contained in the 19S particles of the 26S protea-
somes, as well as the relative content of the X(β5), LMP7(β5i), 
and LMP2(β1i) proteolythic subunits, using corresponding 
antibodies.
In addition to measuring the concentration of proteasome 
subunits in the clarified homogenates of liver and induced 
tumours, we studied the concentration of total proteins and 
β-actin, which are normally used for standardisation of the 
activity and concentration of proteins in tissues. The total 
protein content in the clarified homogenate of hepatocellu-
lar carcinoma was slightly—but reliably—lower than that in 
the clarified homogenate of the intact liver (Table 1). At the 
same time, the β-actin content was significantly higher in the 
hepatocellular carcinoma sample (Fig. 2, Table 1). This meant 
a b c Fig. 1. Hepatic tumors developed under 
chronic regenerative liver condition in the 12 
months after treatment with Dipin followed 
by partial liver resection. a – microadenoma-
 nodule consisting of small hepatocytes with 
diploid nuclei. b – large hepatocellular 
adenoma lacking typical liver lobule and vas-
culature structure. c – trabecular hepatocel-
lular carcinoma with cytomegaly, anomalous 
trabecular and sinusoid structure. H&E stain-
ing. Arrows indicate tumour boundaries. Scale 
bar 100 microns
Table 1. Chymotrypsin-like activity of proteasomes and the content of the proteasome subunits, nNOS, β-actin, and total protein in the clarified ho-
mogenates of mouse liver and induced liver tumors
Parameter
Value in the clarified homogenate of
intact liver liver with hepatic 
nodular hyperplasia adenoma hepatocellular 
carcinoma 
Chymotrypsin-like activity of proteasomes in a 100 
l sample (nanomol Suc-LLVY-AMC)   18.6 ± 1.3 13.7 ± 0.5 11.2 ± 0.5 5.3 ± 0.3
Content of protea-
some subunits (%)
α1,2,3,5,6,7 100 ± 4 135 ± 3 147 ± 2 220 ± 6
Rpt6 100 ± 3   98 ± 3 101 ± 5 150 ± 6
X(5) 100 ± 3 125 ± 5 – 210 ± 8
LMP7(β5i) 100 ± 5 150 ± 4 170 ± 5 169 ± 7
LMP2(β1i) 100 ± 3 200 ± 7 290 ± 17 400 ± 15
nNOS content (%) low 100 ± 3 – 450 ± 13
-actin content (%) 100 ± 2 102 ± 3   97 ± 8 270 ± 7
Protein concentration (mg/ml) 29.5 ± 0.9 26.5 ± 1.1 26.0 ± 0.7 24.0 ± 0.8
A 100% level of proteasome subunits and β-actin corresponds to their content (optical density of bands) in the clarified homogenate of the intact liver; 
A 100% level of nNOS corresponds to its content in the clarified homogenate of the liver with hepatic nodular hyperplasia. The data are represented 
as the average value ± δ. For each data point, p < 0.05, n ≥ 5.RESEARCH ARTICLES
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that in this study both these parameters could not be used as 
an internal reference for the standardisation of the protein 
properties. The more appropriate method would be to com-
pare the activity and concentration of proteasome subunits 
in the control mice liver and hepatic tumours normalised to 
the raw tissue weight.
As an additional reference, we used liver regenerated after 
the partial resection, which was not treated with Dipin. For 
the clarified homogenates of that liver and the intact liver, no 
difference was found in the proteasome chymotrypsin-like 
activity, nor in the content of all studied proteasome subunits, 
β-actin, and total protein (data not shown).
Differences and similarities in the change in the protea-
some pool during benign and malignant tumour formation. 
The changes in the proteasome pool appear as early as when 
diffuse nodules are being formed, manifested by the increase 
of the total proteasome pool and the expression of the X(β5) 
constitutive subunit and the LMP7(β5i) and LMP2(β1i) im-
mune subunits (Fig. 2, Table 1). The extent to which the ex-
pression of these subunits is increased is demonstrated by 
the following pattern: LMP2(β1i) > LMP7(β5i) > X(β5). The 
increase in the LMP2(β1i) subunit content is equal to that 
of the third immune subunit LMP10(β2i), since they are al-
ways incorporated into proteasomes together, whereas the 
LMP7(β5i) immune subunit can be incorporated into protea-
somes independently from the other two [22, 23]. The increase 
in the content of the subunits studied in the total proteasome 
pool was accompanied by a decrease in the total pool activity 
with respect to the Suc-LLVY-AMC oligopeptide hydrolysed 
by the chymotrypsin-like sites of the X(β5) constitutive subu-
nit and the LMP7(β5i) immune subunit (Table 1).
The formation of a malignant tumour caused an even 
stronger decrease in the proteasome chymotrypsin-like ac-
tivity, as well as a stronger increase in the total proteasome 
pool and the content of the immune subunits and the X(β5) 
constitutive subunit (Fig. 2, Table 1). The pattern of the in-
crease of these subunits was different: LMP2(β1i) > X(β5) > 
LMP7(β5i). It should be noted that although the content of 
the LMP7(β5i) immune subunit in the hepatocellular carci-
noma was higher than that in the control liver tissue and the 
liver fragments with diffuse nodules, it was the same as that 
in the adenoma. The content of the total proteasome pool and 
the LMP2(β1i) immune subunit, and the chymotrypsin-like 
activity in the adenoma were at an intermediate level com-
pared to those in the samples of liver with diffuse nodules 
and hepatocellular carcinoma (Fig. 2, Table 1). These results 
indicate that, during the formation of benign and malignant 
tumours, the increase in the total proteasome pool occurs due 
to multiple immunoproteasome forms expressed at different 
ratios. These proteasomes include those containing all three 
immune subunits LMP7(β5i), LMP2(β1i), and LMP10(β2i); 
proteasomes containing the LMP7(β5i) immune subunit and 
the Y(β1) and Z(β2) constitutive subunits; and proteasomes 
containing the X(β5) constitutive subunit and the LMP2(β1i) 
and LMP10(β2i), immune subunits.
The decrease in chymotrypsin-like activity during tumour 
formation cannot be explained only by the change in the ratio 
of the X(β5) and LMP7(β5i) subunits responsible for that type 
of activity, since there is no correlation between those values 
(Table 1). It is likely that incorporation of the LMP2(β1i) sub-
unit into proteasomes and/or intracellular regulation have 
more effect on the chymotrypsin-like activity.
In this study, we uncovered fundamental differences be-
tween proteasome pools in malignant and benign tumours. 
Of all the tumours studied, only hepatocellular carcinoma 
contained an increased amount of the 19S activator, which is 
present in the 26S proteasomes and controls their level (Fig. 
2, Table 1). The increased level of the 26S proteasomes in 
hepatocellular carcinoma is easy to understand. High protein 
metabolism is typical for malignant tumours, including liver 
cancer [24, 25], which, in turn, requires more proteolytic en-
zymes, such as the 26S proteasomes.
The reason for the increased content of immunoprotea-
somes in hepatocellular carcinoma is not so clear, however. 
One can speculate that immunoproteasomes are expressed 
in the transforming cells so that the immune system can rec-
ognise and destroy those cells. It is possible that in our model 
some other links necessary for the immune reaction fail to 
function, and, regardless of the amount of immunoprotea-
somes generated in tumour cells, the immune system could 
destroy the cells. This is one issue we will study further. On 
the other hand, tumour cells may generate immunoproteas-
omes, which are known to possess an antioxidant function, in 
order to protect themselves from metabolites and other fac-
tors that would cause oxidative stress and apoptosis.
Possible mechanism of immunoproteasome regulation in 
tumours. The NO-dependent signalling pathway intended 
for quenching the oxidative stress in endotheliocytes causes 
123kDa
29
Rpt6
LMP7 (β5i)
α1,2,3,5,6,7
LMP2 (β1i)
nNOS
β-actin
X (β5)
45
45
29
20
20
116
Fig. 2. Western blot analysis of proteins in the clarified homogenates of 
the intact liver (1), liver with diffuse nodules (2), and hepatocellular car-
cinoma (3) with use of antibodies to proteasome subunits α1,2,3,5,6,7, 
Rpt6, LMP7(β5i), X(β5), and LMP2(β1i), nNOS and β-actin. Markers: 
carboanhydrase (29 kDa), ovalbumin (45 kDa), trypsin inhibitor (20 kDa), 
and β- galactosidase (116 kDa)106 | ACTA NATURAE |  VOL. 2  № 1 (4)  2010
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additional expression of the LMP2(β1i) immune subunit to 
a larger extent than that of the LMP7(β5i) immune subunit 
[7], which coincides with our results on the expression dy-
namics of immune subunits during hepatic tumourogenesis 
(Table 1). The antioxidative function of immunoproteasomes 
in endotheliocytes is to eliminate the transferrin receptor 
and block free radical oxidation chain reactions involving 
Fe(II) [7]. It has been proven that NO acts as an antioxidant 
in malignant cells, too [26–28]. It is possible that immuno-
proteasomes in hepatocellular carcinoma participate in the 
NO-dependent signalling pathway that protects the tumour 
from oxidative stress. This hypothesis is confirmed by our 
data on the increased expression of nNOS in hepatocellu-
lar carcinoma (Fig. 2, Table 1), while there was little nNOS 
found in the control mouse liver. This result is in accord with 
data in the literature pointing to the fact that the amount of 
nNOS in adult mouse liver drops dramatically compared to 
that in foetal liver, where this enzyme regulates haemat-
opoiesis [29]. 
In this study, we have shown that the formation of tu-
mours in mouse liver is accompanied by significant changes 
in the proteasome pool. These changes are less pronounced in 
nodular hepatic hyperplasia and adenomatosis than in hepa-
tocellular carcinoma. This suggests that nodular hepatic hy-
perplasia and adenomatosis may be stages preceding carcino-
genesis. A schematic representation of a liver cell malignant 
transformation based on our results is given in Fig. 3.
Our results indicate that there is a need to identify the sig-
nalling pathways that change the expression of various pro-
teasome subunits during tumourogenesis. In addition, we can 
conclude that the 19S proteasome activator overexpressed 
in malignant tumours can be a potential target for the de-
velopment of new anticancer drugs. At the moment, the first 
proteasome inhibitor anticancer drug, Bortezomib (Velcade), 
is being used clinically [30]. Bortezomib is injected into a pa-
tient’s bloodstream, and it is administered along with other 
anticancer medication. Bortezomib, a boronic acid derivative, 
selectively inhibits the chymotrypsin-like activity of all pro-
teasome forms and temporarily induces apoptosis, primarily 
of neoplastic cells. The prolonged inhibition of proteasome ac-
tivity, however, induces feedback mechanisms and the gen-
eration of new proteasomes [31]; hence the drug’s temporary 
therapeutic effect. At the same time, Bortezomib affects the 
total proteasome pool in all organs, thus causing side effects 
such as fatigue, atony, gastrointestinal disorders, peripheral 
neuropathy, and significant deterioration of the general well-
being of patients [30]. In this regard, suppressing the func-
tions of the 19S activator while maintaining the proteasome’s 
proteolythic activity appears to be a more efficient and safer 
approach to anticancer therapy.
CONCLUSION
The formation of hepatic nodular regenerative hyperplasia, 
adenomatosis, and carcinoma is accompanied by changes 
Dipin+ partial resection
LIVER TISSUE
LIVER TISSUE 
WITH DIFFUSE 
NODULES
HEPATOCELLULAR 
CARCINOMA
↑19S activator
↑19S activator
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↑↑ LMP2
↑↑ LMP2
↑↑ LMP2
↑ LMP7
↑ LMP7
↑↑ nNOS
↑ nNOS
↑ LMP7
Adenomatosis
Мalignant tumour formation
Мalignant tumour 
formation
Nodular 
regenerative 
hyperplasia
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↑ Total pool ↑ Total pool
↑↑ Total pool
↑↑ Total pool
↓   Chymotrypsin-like 
activity ↓   Chymotrypsin-like activity
↓↓   Chymotrypsin-like activity
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Fig. 3. Schematic representation of liver cell malignant transformation based on the changes in the proteasome poolRESEARCH ARTICLES
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in the proteasome pool, the changes having similarities, as 
well as differences. The similarities are the increase in the 
content of immunoproteasomes and in the total proteasome 
pool, and the decrease in the proteasome chymotrypsin-like 
activity in all tumour types compared to the control sam-
ples. The difference is in the behavior of the 19S proteasome 
activator content, which is increased only in hepatocellular 
carcimona.
The dynamics of changes in the proteasome pools in liver 
with diffuse nodules, adenoma, and carcinoma indicates that 
nodular regenerative hyperplasia and adenomatosis may be 
stages preceding carcinogenesis.
The 19S proteasome activator, which is overexpressed 
only in malignant tumours, can be a promising target for the 
development of new anticancer drugs.  
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